On Monday, 4D Molecular Therapeutics Inc (NASDAQ: FDMT) opened lower -4.33% from the last session, before settling in for the closing price of $2.77. Price fluctuations for FDMT have ranged from $2.67 to $29.26 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 101.44%. Company’s average yearly earnings per share was noted -20.38% at the time writing. With a float of $39.63 million, this company’s outstanding shares have now reached $45.79 million.
Considering the fact that the conglomerate employs 227 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 100.0%, operating margin of -507678.38%, and the pretax margin is -434778.38%.
4D Molecular Therapeutics Inc (FDMT) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of 4D Molecular Therapeutics Inc is 14.40%, while institutional ownership is 91.98%. The most recent insider transaction that took place on Sep 16 ’24, was worth 8,165. In this transaction Chief Legal Officer of this company sold 500 shares at a rate of $16.33, taking the stock ownership to the 6,781 shares. Before that another transaction happened on Aug 19 ’24, when Company’s Chief Legal Officer sold 500 for $15.00, making the entire transaction worth $7,500. This insider now owns 6,781 shares in total.
4D Molecular Therapeutics Inc (FDMT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -20.38% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -4.47% during the next five years compared to -9.89% drop over the previous five years of trading.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Trading Performance Indicators
Check out the current performance indicators for 4D Molecular Therapeutics Inc (FDMT). In the past quarter, the stock posted a quick ratio of 14.92. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3067.59.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.16, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -3.81 in one year’s time.
Technical Analysis of 4D Molecular Therapeutics Inc (FDMT)
Compared to the last year’s volume of 0.82 million, its volume of 1.02 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 8.08%. Additionally, its Average True Range was 0.33.
During the past 100 days, 4D Molecular Therapeutics Inc’s (FDMT) raw stochastic average was set at 2.83%, which indicates a significant decrease from 12.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 89.23% in the past 14 days, which was higher than the 83.13% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.37, while its 200-day Moving Average is $10.08. Nevertheless, the first resistance level for the watch stands at $2.78 in the near term. At $2.91, the stock is likely to face the second major resistance level. The third major resistance level sits at $3.07. If the price goes on to break the first support level at $2.49, it is likely to go to the next support level at $2.33. Now, if the price goes above the second support level, the third support stands at $2.20.
4D Molecular Therapeutics Inc (NASDAQ: FDMT) Key Stats
There are currently 46,302K shares outstanding in the company with a market cap of 122.70 million. Presently, the company’s annual sales total 40 K according to its annual income of -160,870 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -43,840 K.
